We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Chemotherapy With DNA Damaging Agents In Colorectal Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01456923
Recruitment Status : Completed
First Posted : October 21, 2011
Last Update Posted : October 21, 2011
Information provided by (Responsible Party):
Ana Cadavez Pedro, Centro Hospitalar Nordeste

Brief Summary:
Chemotherapy Treatment alone with DNA damaging drugs might be as effective as chemotherapy combined with surgery in colorectal cancer (CRC) avoiding surgery complications.

Condition or disease Intervention/treatment Phase
Colorectal Cancer Other: Treatment with chemotherapy Other: Only chemotherapy treatment for study cohort Procedure: surgery Phase 1

Study Type : Interventional  (Clinical Trial)
Primary Purpose: Treatment
Official Title: Phase 1 Study Of The Efficacy Of Chemotherapy With DNA Damaging Agents Versus Surgery In Colorectal Cancer

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arm Intervention/treatment
Active Comparator: Control (chemotherapy and surgery)
Patients treated with chemotherapy + surgery
Other: Treatment with chemotherapy Procedure: surgery
Active Comparator: Study
Patients treated only with chemotherapy
Other: Only chemotherapy treatment for study cohort
Control patients were treated both with surgery and chemotherapy. Study patients were treated only with chemotherapy

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   40 Years to 90 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

- patients that did not underwent surgery

Exclusion Criteria:

- patients that underwent surgery

Responsible Party: Ana Cadavez Pedro, Principal Investigator, Centro Hospitalar Nordeste
ClinicalTrials.gov Identifier: NCT01456923     History of Changes
Other Study ID Numbers: ACCRC10
First Posted: October 21, 2011    Key Record Dates
Last Update Posted: October 21, 2011
Last Verified: September 2008

Keywords provided by Ana Cadavez Pedro, Centro Hospitalar Nordeste:
DNA damaging agents

Additional relevant MeSH terms:
Colorectal Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Gastrointestinal Diseases
Colonic Diseases
Intestinal Diseases
Rectal Diseases